About Novan
Novan is a company based in Morrisville (United States) founded in 2006. Novan has raised $164.84 million across 30 funding rounds from investors including NIH, HHS and Ligand Pharmaceuticals. The company has 89 employees. Novan has completed 1 acquisition, including EPI Health. Novan offers products and services including ZELSUVMI, SB204, and NITRICIL. Novan operates in a competitive market with competitors including Incyte, LEO Pharma, Formation Bio, Arcutis and Inovio Pharmaceuticals, among others.
- Annual Revenue$23.68 M (USD)701as on Dec 31, 2022
- Net Profit-$31.31 M (USD)-5as on Dec 31, 2022
- EBITDA-$34.23 M (USD)-14as on Dec 31, 2022
- Total Equity Funding$164.84M (USD)
in 30 rounds
- Latest Funding Round$5M (USD), Post-IPO
Jul 2020
- InvestorsNIH
& 8 more
- Employee Count89
- Investments & Acquisitions
Products & Services of Novan
Novan offers a comprehensive portfolio of products and services, including ZELSUVMI, SB204, and NITRICIL.
Treatment for molluscum contagiosum skin infection
Nitric oxide-based therapy for skin conditions
Innovative nitric oxide technology for dermatological treatments
Funding Insights of Novan
Novan has successfully raised a total of $164.84M across 30 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $164.84M
- Total Rounds 30
- Last Round Post-IPO — $5M
- First Round $2.67M
(Apr 2007)
- Investors Count 9
Latest 10 of 30 funding rounds of Novan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
9 investors in total: 8 institutional and 1 angel.
Investors in Novan
Novan has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, HHS and Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | aspirecapital.com | - | |
Venture capital fund backed by the US Government | – | seedfund.nsf.gov | Alexandria, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Military forces are provided by the U.S. Department of Defense for national security. | – | defense.gov | Washington, D.C., United States | |
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States | |
Malin PLC is engaged in investing in life sciences companies. | – | malinplc.com | Dublin, Ireland | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
JP John Palmour | - | – | unknown_020bf6be032145f0b | - |
Investor details for Novan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Novan
14 people are tracked at Novan (7 in leadership, 5 in board & advisors, 2 in team); the tracked headcount is 89.
| Name | Role | Group |
|---|---|---|
Paula Brown Stafford | CEO & President | Leadership |
Martina Cartwright | Vice President, Medical Affairs | Leadership |
Matt Carey | Director, Facilities Engineering And EHS | Leadership |
Carolyn Enloe | Associate Director, Medical Scientific Communications | Leadership |
Melvin Whitehead | Senior Vice President, Operations | Leadership |
Robert Hill | Senior Director Of Finance And Commercial Controller | Leadership |
Tomoko Maeda-Chubachi | VP, Medical Dermatology | Leadership |
Steve Skolsky | Director | Board & advisors |
Machelle Sanders | Director | Board & advisors |
W. Kent Geer | Lead Independent Director | Board & advisors |
Steven D. Skolsky | Director | Board & advisors |
Robert J. Keegan | Director | Board & advisors |
Amphone Pun | Accounting Manager | Team |
Carly Lee | Manager, Business Operations, Contracts And Outsourcing | Team |
Complete people profiles for Novan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novan
Novan has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EPI Health.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Innovative therapeutic treatments for skin diseases are developed. | epihealth.com | Charleston, United States | 2017 | Mar 2022 | •••• |
Complete acquisition details for Novan
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Novan
5 dated milestones of Novan across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Novan is founded.
- Funding First funding round of $2.7M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $5.0M.
- Acquisition Acquires EPI Health.
Competitors of Novan
Novan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Incyte, LEO Pharma, Formation Bio, Arcutis and Inovio Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| leo-pharma.com | 1908 | Copenhagen, Denmark | $560.38M | 142 | Developer of drugs for treating dermatology diseases | |
| formation.bio | 2016 | New York, United States | $608M | – | AI-powered drug discovery platform for various diseases | |
| arcutis.com | 2016 | Westlake Village, United States | $94.5M | 296 | Immunotherapeutic solutions for dermatological conditions are developed. | |
| inovio.com | 1983 | Plymouth Meeting, United States | – | 275 | Developer of vaccines for the treatment of cancer and infectious diseases | |
| dermbiont.com | 2015 | Melrose, United States | $78.91M | 14 | Microbial therapeutics for skin diseases are developed. | |
| evommune.com | 2020 | Sacramento, United States | $275.5M | – | Developer of therapeutic options for chronic inflammatory disorders | |
| edesabiotech.com | 2015 | Toronto, Canada | – | 49 | Topical therapeutics for dermatological and gastrointestinal diseases are developed. | |
| azitrainc.com | 2014 | Farmington, United States | $37.4M | 17 | Microbiome-based therapeutics for skin conditions like eczema are developed. |
Detailed competitors of Novan
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novan
Complete news archive for Novan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Novan
10 companies that operate in the same segment as Novan (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Novan
Novan was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Novan is headquartered in Morrisville, United States.
Paula Brown Stafford is the current CEO of Novan.
Novan is a funded company, having raised a total of $164.84M across 30 funding rounds to date. The company's 1st funding round was a Series C of $50M, raised on Apr 2007.
Novan has 89 employees.
Annual revenue of Novan is $23.68M as on Dec 31, 2022.
Novan was founded in 2006 and is headquartered in Morrisville, United States. Therapeutics based on nitric oxide are developed by the company for various dermatology conditions. The proprietary Nitricil platform is utilized to create novel nitric oxide-based new chemical entities for topical applications. A lead candidate targets acne vulgaris, while other programs address human papillomavirus infections, onychomycosis, psoriasis, and atopic dermatitis.
Novan's top competitors include LEO Pharma, Formation Bio and Arcutis.
Novan offers ZELSUVMI, SB204, and NITRICIL.
Novan has made 1 acquisition, including EPI Health.
Novan has 9 investors. Key investors include NIH, HHS, Ligand Pharmaceuticals, Aspire Capital, and U.S. Department of Defense.
Novan operates through Novan, Inc..